双膦酸盐治疗变化趋势:美国单一整合医疗系统25年监测
在Kaiser Permanente北加州系统1998-2022年间,212,289名50-89岁成人启动双膦酸盐治疗,其中86.0%为女性。随时间推移,启动治疗者向高龄和既往骨折人群集中,女性既往骨折比例从21-24%升至35-38%,男性从28%升至47%后于2018-2022年降至26%。
要点
- 25年间启动双膦酸盐者向高龄和既往骨折人群集中,反映骨折预防策略变化。
- 女性既往骨折比例从1998-2007年的21-24%升至2008-2022年的35-38%。
- 男性既往骨折比例从28%升至47%后,在2018-2022年降至26%。
核心结论
- 在大型初级保健成人双膦酸盐启动人群中,对高龄和既往骨折者治疗增加,凸显针对性骨折预防措施的关键作用,维持治疗努力。
研究设计与样本
- 在Kaiser Permanente北加州系统1998-2022年间,对50-89岁启动阿仑膦酸、利塞膦酸、伊班膦酸或唑来膦酸的成人进行25年趋势分析,检查年龄、性别、种族和民族及骨折史,按5年时期评估。
主要发现
- 共212,289名成人(86.0%女性)在1998-2022年间启动双膦酸盐。
- 2008年后,启动双膦酸盐成人中年龄<65岁者比例大幅降低;女性各连续5年时期<65岁百分比分别为35.1%、35.2%、24.1%、18.8%、17.8%。
- 男性各连续5年时期<65岁百分比分别为26.9%、25.4%、17.6%、12.6%、4.7%。
- 女性启动双膦酸盐者既往骨折比例从1998-2007年的21-24%增至2008-2022年的35-38%(2008年实施女性二级骨折预防项目后)。
- 男性既往骨折比例在1998-2017年各连续5年时期从28%升至37%、40%、47%(男性二级骨折预防项目始于2015年),但在2018-2022年降至26%(骨密度筛查针对老年男性后)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In a single, large integrated US healthcare system, bisphosphonate treatment initiation for fracture prevention among older adults shifted towards higher-risk populations over a 25-year time period (1998-2022). The temporal trends among women and men who initiated treatment reflected changing practice patterns and both primary and secondary fracture prevention efforts. INTRODUCTION: While bisphosphonate (BP) drugs remain first-line for fracture prevention, treatment has changed over time. This study examines trends over 25 years among adults initiating BP in a single healthcare system. METHODS: Among adults aged 50-89 years who initiated alendronate, risedronate, ibandronate, or zoledronate in Kaiser Permanente Northern California during 1998-2022, age, sex, race and ethnicity, and fracture history were examined. Findings across 5-year periods were evaluated. RESULTS: A total of 212,289 adults (86.0% women) initiated BP during 1998-2022. After 2008, a much lower proportion of adults who initiated BP were age < 65 years. Across successive 5-year periods, the percentages of women who were age < 65 years were 35.1%, 35.2%, 24.1%, 18.8%, and 17.8%. Among men, these percentages were 26.9%, 25.4%, 17.6%, 12.6%, and 4.7%. In later years, sustained or increasing numbers of adults initiating BP coincided with electronic health record targets for BMD screening (since 2016 for women, 2017-2019 for men), an impact greater for men. The proportions with prior fracture among women initiating BP increased from 21-24% (1998-2007) to 35-38% (2008-2022) after implementing a secondary fracture prevention program for women in 2008. Among men, this proportion increased from 28 to 37%, 40%, and 47% during successive 5-year periods in 1998-2017 (the secondary fracture prevention program for men began in 2015) but fell to 26% in 2018-2022 after BMD screening targeted older men. CONCLUSIONS: In a large primary care population of adults initiating BP, greater treatment of older adults and those with prior fracture highlights the key role of targeted fracture prevention initiatives, sustaining treatment efforts.
引用
- Lo JC, Chandra M, Khan MM, et al. Changing trends in bisphosphonate therapy: a twenty-five-year surveillance in a single US integrated healthcare system. Osteoporos Int. 2025. PMID: 39915333. doi:10.1007/s00198-024-07372-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。